Domingo Francisco Javier DÃ-ez MartÃ

List of Publications by Year
in descending order

308 papers	19,354 citations	7568 77 h-index	15732 125 g-index
326 all docs	326 docs citations	326 times ranked	19602 citing authors

#	Article	IF	Citations
1	Heart failure in chronic kidney disease: the emerging role of myocardial fibrosis. Nephrology Dialysis Transplantation, 2022, 37, 817-824.	0.7	15
2	Management of cardiac fibrosis is the largest unmet medical need in heart failure. Cardiovascular Research, 2022, 118, e20-e22.	3.8	23
3	Transition to heart failure in hypertension: going to the heart of the matter. European Heart Journal, 2022, 43, 3332-3334.	2.2	6
4	Biomarkerâ€based assessment of collagen crossâ€linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the <scp>HOMAGE</scp> clinical trial. European Journal of Heart Failure, 2022, 24, 321-331.	7.1	16
5	The unmet need of evidence-based therapy for patients with advanced chronic kidney disease and heart failure. CKJ: Clinical Kidney Journal, 2022, 15, 865-872.	2.9	16
6	MO747: Endotrophin Levels are Extremely Elevated in Dialysis Patients with Heart Failure with Preserved Ejection Fraction (HFPEF) and are Influenced by Background Treatment with Diuretics and ARBS/ACEI. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
7	A Fibrosis Biomarker Early Predicts Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy. Cancers, 2022, 14, 2941.	3.7	4
8	The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trial. European Journal of Heart Failure, 2022, 24, 1559-1568.	7.1	12
9	Glucose-Dependent Insulinotropic Peptide in the High-Normal Range Is Associated With Increased Carotid Intima-Media Thickness. Diabetes Care, 2021, 44, 224-230.	8.6	20
10	Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches. Nature Reviews Cardiology, 2021, 18, 479-498.	13.7	128
11	The need for a cardionephrology subspecialty. CKJ: Clinical Kidney Journal, 2021, 14, 1491-1494.	2.9	12
12	Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF. JACC: Heart Failure, 2021, 9, 268-277.	4.1	46
13	MO734CONTRIBUTION OF SOLUBLE ST2 TO THE EFFECT OF RIGHT VENTRICULAR DYSFUNCTION ON MORTALITY IN HEMODIALYSIS PATIENTS. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
14	Urinary peptides in heart failure: a link to molecular pathophysiology. European Journal of Heart Failure, 2021, 23, 1875-1887.	7.1	37
15	Bases para la creaciÃ³n de las unidades clÃnicas cardiorrenales. Documento de consenso de los grupos de trabajo cardiorrenal de la SEC y la SEN. REC: CardioClinics, 2021, 56, 284-295.	0.1	8
16	Heart failure-related skeletal myopathy. Potential involvement of myokines. Revista Espanola De Cardiologia (English Ed), 2021, 74, 1008-1012.	0.6	1
17	The combination of carboxyâ€terminal propeptide of procollagen type I blood levels and late gadolinium enhancement at cardiac magnetic resonance provides additional prognostic information in idiopathic dilated cardiomyopathyÂâ€“ÂA multilevel assessment of myocardial fibrosis in dilated cardiomyopathy. European Journal of Heart Failure, 2021, 23, 933-944.	7.1	34
18	Identification of sexâ€specific biomarkers predicting newâ€onset heart failure. ESC Heart Failure, 2021, 8, 3512-3520.	3.1	11

#	Article	IF	Citations
19	Developing the subspecialty of cardio-nephrology: The time has come. A position paper from the coordinating committee from the Working Group for Cardiorenal Medicine of the Spanish Society of Nephrology. Nefrologia, 2021, 41, 391-402.	0.4	3
20	MiopatÃa esquelÃ©tica en la insuficiencia cardiaca. ImplicaciÃ³n potencial de las miocinas. Revista Espanola De Cardiologia, 2021, 74, 1009-1009.	1.2	0
21	Deficiency of Procollagen C-Proteinase Enhancer 1 in Mice has No Major Impact on Cardiac Collagen and Function Under Basal Conditions. Journal of Cardiovascular Pharmacology, 2021, 78, e703-e713.	1.9	4
22	Galectin-3 Inhibition With Modified Citrus Pectin in Hypertension. JACC Basic To Translational Science, 2021, 6, 12-21.	4.1	28
23	Serum and urinary biomarkers of collagen typeâ€‰ turnover predict prognosis in patients with heart failure. Clinical and Translational Medicine, 2021, 11, e267.	4.0	10
24	The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart â€˜OMicsâ€™ in AGEing (HOMAGE) randomized clinical trial. European Heart Journal, 2021, 42, 684-696.	2.2	77
25	Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review. Frontiers in Cardiovascular Medicine, 2021, 8, 754499.	2.4	30
26	Developing the subspecialty of cardio-nephrology: The time has come. A position paper from the coordinating committee from the Working Group for Cardiorenal Medicine of the Spanish Society of Nephrology. Nefrologia, 2021, 41, 391-402.	0.4	3
27	Plasma protein biomarkers and their association with mutually exclusive cardiovascular phenotypes: the FIBRO-TARGETS caseâ€“control analyses. Clinical Research in Cardiology, 2020, 109, 22-33.	3.3	19
28	Reprint of â€œThe complex dynamics of myocardial interstitial fibrosis in heart failure. Focus on collagen cross-linkingâ€. Biochimica Et Biophysica Acta - Molecular Cell Research, 2020, 1867, 118521.	4.1	7
29	Burden and challenges of heart failure in patients with chronic kidney disease. A call to action. Nefrologia, 2020, 40, 223-236.	0.4	21
30	Myocardial interstitial fibrosis in the era of precision medicine. Biomarker-based phenotyping for a personalized treatment. Revista Espanola De Cardiologia (English Ed), 2020, 73, 248-254.	0.6	4
31	Burden and challenges of heart failure in patients with chronic kidney disease. A call to action. Nefrologia, 2020, 40, 223-236.	0.4	7
32	Role of Cardiac Lymphatics in MyocardialÂEdema and Fibrosis. Journal of the American College of Cardiology, 2020, 76, 735-744.	2.8	45
33	Cardiac magnetic resonance-derived fibrosis, strain and molecular biomarkers of fibrosis in hypertensive heart disease. Journal of Hypertension, 2020, 38, 2036-2042.	0.5	17
34	Hypertrophic cardiomyopathy in myosin-binding protein C (MYBPC3) Icelandic founder mutation carriers. Open Heart, 2020, 7, e001220.	2.3	10
35	Does Chronic Kidney Disease Facilitate Malignant Myocardial Fibrosis in Heart Failure with Preserved Ejection Fraction of Hypertensive Origin?. Journal of Clinical Medicine, 2020, 9, 404.	2.4	15
36	Glucose-dependent insulinotropic peptide and risk of cardiovascular events and mortality: a prospective study. Diabetologia, 2020, 63, 1043-1054.	6.3	18

#	Article	IF	Citations
37	Natural Compound Library Screening Identifies New Molecules for the Treatment of Cardiac Fibrosis and Diastolic Dysfunction. Circulation, 2020, 141, 751-767.	1.6	48
38	Cardiorenal interaction and heart failure outcomes. A role for insulin-like growth factor binding protein 2?. Revista Espanola De Cardiologia (English Ed), 2020, 73, 835-843.	0.6	5
39	Myocardial Interstitial Fibrosis in Nonischemic Heart Disease, Part 3/4. Journal of the American College of Cardiology, 2020, 75, 2204-2218.	2.8	63
40	La fibrosis intersticial miocÃ¡rdica en la era de la medicina de precisiÃ³n. El fenotipado basado en biomarcadores para un tratamiento personalizado. Revista Espanola De Cardiologia, 2020, 73, 248-254.	1.2	8
41	Myocardial fibrosis as a matter of cell differentiation: opportunities for new antifibrotic strategies. European Heart Journal, 2019, 40, 979-981.	2.2	7
42	Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure. Heart, 2019, 105, 307-314.	2.9	28
43	Why Clinicians Should Care About theÂCardiac Interstitium. JACC: Cardiovascular Imaging, 2019, 12, 2305-2318.	5.3	20
44	Biomarkers of Cardiovascular Disease. , 2019, , 319-330.		0
45	Circulating Long Noncoding RNA LIPCAR Predicts Heart Failure Outcomes in Patients Without Chronic Kidney Disease. Hypertension, 2019, 73, 820-828.	2.7	41
46	Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 272-285.	7.1	182
47	Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure. Circulation: Heart Failure, 2019, 12, e005897.	3.9	63
48	The complex dynamics of myocardial interstitial fibrosis in heart failure. Focus on collagen cross-linking. Biochimica Et Biophysica Acta - Molecular Cell Research, 2019, 1866, 1421-1432.	4.1	50
49	Association of left atrium voltage amplitude and distribution with the risk of atrial fibrillation recurrence and evolution after pulmonary vein isolation: An ultrahighâ€density mapping study. Journal of Cardiovascular Electrophysiology, 2019, 30, 1231-1240.	1.7	8
50	Combination of Circulating Type I Collagen-Related Biomarkers Is AssociatedÂWith AtrialÂFibrillation. Journal of the American College of Cardiology, 2019, 73, 1398-1410.	2.8	54
51	The Interleukin-1 Axis and Risk of Death inÂPatients With Acutely DecompensatedÂHeart Failure. Journal of the American College of Cardiology, 2019, 73, 1016-1025.	2.8	52
52	Cardioprotective Effect of the Mitochondrial Unfolded Protein Response During Chronic Pressure Overload. Journal of the American College of Cardiology, 2019, 73, 1795-1806.	2.8	97
53	Characterization of biventricular alterations in myocardial (reverse) remodelling in aortic banding-induced chronic pressure overload. Scientific Reports, 2019, 9, 2956.	3.3	11
54	CT-1 (Cardiotrophin-1)-Gal-3 (Galectin-3) Axis in Cardiac Fibrosis and Inflammation. Hypertension, 2019, 73, 602-611.	2.7	78

#	Article	IF	Citations
55	Circulating Biomarkers Predicting Longitudinal Changes in Left Ventricular Structure and Function in a General Population. Journal of the American Heart Association, 2019, 8, e010430.	3.7	5
56	Increased Fibroblast Growth Factor 23 in Heart Failure: Biomarker, Mechanism, or Both?. American Journal of Hypertension, 2019, 32, 15-17.	2.0	3
57	The renal immune-inflammatory component of arterial hypertension: emerging therapeutic strategies. Cardiovascular Research, 2019, 115, 696-698.	3.8	2
58	Aging and atrial fibrillation: a matter of fibrosis. Aging, 2019, 11, 9965-9966.	3.1	16
59	Myocardial Interstitial Fibrosis in HeartÂFailure. Journal of the American College of Cardiology, 2018, 71, 1696-1706.	2.8	406
60	Reverse Myocardial Remodeling FollowingÂValve Replacement in PatientsÂWith Aortic Stenosis. Journal of the American College of Cardiology, 2018, 71, 860-871.	2.8	266
61	Reappraising myocardial fibrosis in severe aortic stenosis: an invasive and non-invasive study in 133 patients. European Heart Journal, 2018, 39, 699-709.	2.2	178
62	MicroRNA-221/222 Family Counteracts Myocardial Fibrosis in Pressure Overloadâ€“Induced Heart Failure. Hypertension, 2018, 71, 280-288.	2.7	128
63	Biomarkerâ€based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldoâ€DHF trial. European Journal of Heart Failure, 2018, 20, 1290-1299.	7.1	64
64	Transitioning from usual care to biomarker-based personalized and precision medicine in heart failure: call for action. European Heart Journal, 2018, 39, 2793-2799.	2.2	26
65	Osteoglycin prevents the development of age-related diastolic dysfunction during pressure overload by reducing cardiac fibrosis and inflammation. Matrix Biology, 2018, 66, 110-124.	3.6	39
66	Rationale of the FIBROTARGETS study designed to identify novel biomarkers of myocardial fibrosis. ESC Heart Failure, 2018, 5, 139-148.	3.1	21
67	Investigating a biomarkerâ€driven approach to target collagen turnover in diabetic heart failure with preserved ejection fraction patients. Effect of torasemide versus furosemide on serum Câ€terminal propeptide of procollagen type I (DROPâ€PIP trial). European Journal of Heart Failure, 2018, 20, 460-470.	7.1	29
68	Sex Dimorphism in the MyocardialÂResponse to Aortic Stenosis. JACC: Cardiovascular Imaging, 2018, 11, 962-973.	5.3	85
69	Myocardial Remodeling in Hypertension. Hypertension, 2018, 72, 549-558.	2.7	123
70	Immunomodulation by adoptive regulatory Tâ€cell transfer improves Coxsackievirus B3â€induced myocarditis. FASEB Journal, 2018, 32, 6066-6078.	0.5	42
71	Unraveling New Mechanisms of Renal Fibrosis With Potential Therapeutic Implications. Hypertension, 2018, 72, 277-278.	2.7	1
72	Reply. Journal of the American College of Cardiology, 2018, 71, 2984-2985.	2.8	0

#	Article	IF	Citations
73	Role of Myocardial Collagen in Severe Aortic Stenosis With Preserved Ejection Fraction and Symptoms of Heart Failure. Revista Espanola De Cardiologia (English Ed), 2017, 70, 832-840.	0.6	18
74	Mechanisms underlying the cardiac antifibrotic effects of losartan metabolites. Scientific Reports, 2017, 7, 41865.	3.3	21
75	Myocardial fibrosis: biomedical research from bench to bedside. European Journal of Heart Failure, 2017, 19, 177-191.	7.1	280
76	MicroRNA-19b is a potential biomarker of increased myocardial collagen cross-linking in patients with aortic stenosis and heart failure. Scientific Reports, 2017, 7, 40696.	3.3	39
77	Impact of acute hypertension transients on diastolic function in patients with heart failure with preserved ejection fraction. Cardiovascular Research, 2017, 113, 906-914.	3.8	20
78	Increased phagocytic NADPH oxidase activity associates with coronary artery calcification in asymptomatic men. Free Radical Research, 2017, 51, 389-396.	3.3	18
79	Risk for Incident Heart Failure: A Subjectâ€Level Metaâ€Analysis From the Heart â€œOMicsâ€•in AGEing (HOMAGE) Study. Journal of the American Heart Association, 2017, 6, .	3.7	41
80	Phenotyping of myocardial fibrosis in hypertensive patients with heart failure. Influence on clinical outcome. Journal of Hypertension, 2017, 35, 853-861.	0.5	58
81	Myocardial fibrosis in response to pressure overload: elucidating the contribution of tissue transglutaminase. Cardiovascular Research, 2017, 113, 841-843.	3.8	5
82	A Urinary Fragment of Mucin-1 Subunit Î± Is a Novel Biomarker Associated With Renal Dysfunction in the General Population. Kidney International Reports, 2017, 2, 811-820.	0.8	24
83	Epicardial Adipose Tissue in the General Middle-aged Population and Its Association With Metabolic Syndrome. Revista Espanola De Cardiologia (English Ed), 2017, 70, 254-260.	0.6	15
84	Usefulness of Collagen Carboxy-Terminal Propeptide and Telopeptide to Predict Disturbances of Long-Term Mortality in Patients â‰¥60ÂYears With Heart Failure and Reduced Ejection Fraction. American Journal of Cardiology, 2017, 119, 2042-2048.	1.6	24
85	Papel del colÃ¡geno miocÃ¡rdico en la estenosis aÃ³rtica grave conÂfracciÃ³n deÂeyecciÃ³n conservada yÂsÃntomas deÂinsuficiencia cardiaca. Revista Espanola De Cardiologia, 2017, 70, 832-840.	1.2	26
86	Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction. JAMA Cardiology, 2017, 2, 995.	6.1	164
87	Cartilage intermediate layer protein 1 (CILP1): A novel mediator of cardiac extracellular matrix remodelling. Scientific Reports, 2017, 7, 16042.	3.3	37
88	Biomarkers of cardiovascular stress and fibrosis in preclinical hypertrophic cardiomyopathy. Open Heart, 2017, 4, e000615.	2.3	22
89	Compelling Benefit of Soluble Suppression of Tumorigenicityâ€2 in Postâ€“Myocardial Infarction Estimation of Risk: The Time Is Right for Its Routine Use in the Clinic. Journal of the American Heart Association, 2017, 6, .	3.7	7
90	The Hypertensive Myocardium. Medical Clinics of North America, 2017, 101, 43-52.	2.5	21

#	Article	IF	Citations
91	Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy. European Journal of Heart Failure, 2017, 19, 167-176.	7.1	91
92	Association of cystatin C with heart failure with preserved ejection fraction in elderly hypertensive patients. Journal of Hypertension, 2016, 34, 130-138.	0.5	30
93	What is on the horizon for improved treatments for acutely decompensated heart failure?. European Heart Journal Supplements, 2016, 18, G33-G42.	0.1	0
94	Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment. Nature Communications, 2016, 7, 13710.	12.8	190
95	Understanding the Role of CCN Matricellular Proteins in Myocardial Fibrosis â^—. Journal of the American College of Cardiology, 2016, 67, 1569-1571.	2.8	4
96	Targeting the Cardiac Myofibroblast Secretome to Treat Myocardial Fibrosis in Heart Failure. Circulation: Heart Failure, 2016, 9, .	3.9	19
97	Potential role of microRNA-10b down-regulation in cardiomyocyte apoptosis in aortic stenosis patients. Clinical Science, 2016, 130, 2139-2149.	4.3	12
98	Myocardial Collagen Cross-Linking IsÂAssociated With Heart Failure Hospitalization in Patients With Hypertensive Heart Failure. Journal of the American College of Cardiology, 2016, 67, 251-260.	2.8	127
99	Serelaxin for the treatment of acute heart failure: a review with a focus on end-organ protection. European Heart Journal - Cardiovascular Pharmacotherapy, 2016, 2, 119-130.	3.0	21
100	DPP-4 inhibition and blood pressure lowering in perspective. Journal of Hypertension, 2016, 34, 184-187.	0.5	4
101	Diastolic Left Ventricular Function in Relation to Urinary and Serum Collagen Biomarkers in a General Population. PLoS ONE, 2016, 11, e0167582.	2.5	22
102	Searching for new mechanisms of myocardial fibrosis with diagnostic and/or therapeutic potential. European Journal of Heart Failure, 2015, 17, 764-771.	7.1	109
103	Targeting Î³-secretases protect against angiotensin II-induced cardiac hypertrophy. Journal of Hypertension, 2015, 33, 843-850.	0.5	9
104	Myocardial Fibrosis Quantified by Extracellular Volume Is Associated With Subsequent Hospitalization for Heart Failure, Death, or Both Across the Spectrum of Ejection Fraction and Heart Failure Stage. Journal of the American Heart Association, 2015, 4, .	3.7	174
105	Diltiazem Treatment for Pre-Clinical Hypertrophic Cardiomyopathy SarcomereÂMutation Carriers. JACC: Heart Failure, 2015, 3, 180-188.	4.1	137
106	Association of low GLP-1 with oxidative stress is related to cardiac disease and outcome in patients with type 2 diabetes mellitus: A pilot study. Free Radical Biology and Medicine, 2015, 81, 1-12.	2.9	27
107	Circulating Biomarkers of Myocardial Fibrosis. Journal of the American College of Cardiology, 2015, 65, 2449-2456.	2.8	196
108	Galectinâ€3 and histological, molecular and biochemical aspects of myocardial fibrosis in heart failure of hypertensive origin. European Journal of Heart Failure, 2015, 17, 385-392.	7.1	54

#	Article	IF	Citations
109	Biomarkers of cardiomyocyte injury and stress identify left atrial and left ventricular remodelling and dysfunction: A population-based study. International Journal of Cardiology, 2015, 185, 177-185.	1.7	31
110	â€œTargeting the Heartâ€•in Heart Failure. JACC: Heart Failure, 2015, 3, 661-669.	4.1	50
111	El tratamiento de la insuficiencia cardÃaca con fracciÃ³n de eyecciÃ³n preservada. Un problema sin resolver. Revista Clinica Espanola, 2015, 215, 320-321.	0.6	2
112	microRNA-122 down-regulation may play a role in severe myocardial fibrosis in human aortic stenosis through TGF-Î²1 up-regulation. Clinical Science, 2014, 126, 497-506.	4.3	80
113	Association of Phagocytic NADPH Oxidase Activity With Hypertensive Heart Disease. Hypertension, 2014, 63, 468-474.	2.7	16
114	Association of Cardiotrophin-1 With Myocardial Fibrosis in Hypertensive Patients With Heart Failure. Hypertension, 2014, 63, 483-489.	2.7	48
115	Biomarkers of collagen type I metabolism are related to B-type natriuretic peptide, left ventricular size, and diastolic function in heart failure. Journal of Cardiovascular Medicine, 2014, 15, 463-469.	1.5	26
116	Cooperative Research in Biomedicine. Spain's Cardiovascular Network, Red de InvestigaciÃ³n Cardiovascular. Revista Espanola De Cardiologia (English Ed), 2014, 67, 254-258.	0.6	1
117	Arterial Hypertension in Patients with Heart Failure. Heart Failure Clinics, 2014, 10, 233-242.	2.1	16
118	Epicardial delivery of collagen patches with adipose-derived stem cells in rat and minipig models of chronic myocardial infarction. Biomaterials, 2014, 35, 143-151.	11.4	90
119	Downregulation of G protein-coupled receptor kinase 2 levels enhances cardiac insulin sensitivity and switches on cardioprotective gene expression patterns. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 2448-2456.	3.8	38
120	New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. European Heart Journal, 2014, 35, 2797-2815.	2.2	304
121	Atrial fibrillation and biomarkers of myocardial fibrosis in heart failure. Scandinavian Cardiovascular Journal, 2014, 48, 299-303.	1.2	17
122	Serelaxin: A Novel Therapy for Acute Heart Failure with a Range of Hemodynamic and Non-Hemodynamic Actions. American Journal of Cardiovascular Drugs, 2014, 14, 275-285.	2.2	25
123	Heart â€˜omicsâ€™ in AGEing (HOMAGE): design, research objectives and characteristics of the common database. Journal of Biomedical Research, 2014, 28, 349.	1.6	24
124	The activity of circulating dipeptidyl peptidase-4 is associated with subclinical left ventricular dysfunction in patients with type 2 diabetes mellitus. Cardiovascular Diabetology, 2013, 12, 143.	6.8	24
125	T1 Measurements Identify Extracellular Volume Expansion in Hypertrophic Cardiomyopathy Sarcomere Mutation Carriers With and Without Left Ventricular Hypertrophy. Circulation: Cardiovascular Imaging, 2013, 6, 415-422.	2.6	195
126	A Synthetic Peptide from Transforming Growth Factor-Î²₁Type III Receptor Inhibits NADPH Oxidase and Prevents Oxidative Stress in the Kidney of Spontaneously Hypertensive Rats. Antioxidants and Redox Signaling, 2013, 19, 1607-1618.	5.4	21

#	Article	IF	Citations
127	Myocardial Titin Hypophosphorylation Importantly Contributes to Heart Failure With Preserved Ejection Fraction in a Rat Metabolic Risk Model. Circulation: Heart Failure, 2013, 6, 1239-1249.	3.9	241
128	Osteopontin-mediated myocardial fibrosis in heart failure: a role for lysyl oxidase?. Cardiovascular Research, 2013, 99, 111-120.	3.8	113
129	Decreased Nox4 levels in the myocardium of patients with aortic valve stenosis. Clinical Science, 2013, 125, 291-300.	4.3	14
130	Absence of Cardiotrophin 1 Is Associated With Decreased Age-Dependent Arterial Stiffness and Increased Longevity in Mice. Hypertension, 2013, 61, 120-129.	2.7	42
131	Association of cardiotrophin-1 with left ventricular systolic properties in asymptomatic hypertensive patients. Journal of Hypertension, 2013, 31, 587-594.	0.5	17
132	Cardiotrophin 1 Is Involved in Cardiac, Vascular, and Renal Fibrosis and Dysfunction. Hypertension, 2012, 60, 563-573.	2.7	55
133	Collagen Cross-Linking But Not Collagen Amount Associates With Elevated Filling Pressures in Hypertensive Patients With Stage C Heart Failure. Hypertension, 2012, 60, 677-683.	2.7	170
134	Cardiotrophin-1 induces sarcoplasmic reticulum Ca2+ leak and arrhythmogenesis in adult rat ventricular myocytes. Cardiovascular Research, 2012, 96, 81-89.	3.8	22
135	Contribution of circulating biomarkers to unravel the role of extracellular matrix in hypertensive cardiac remodelling. Journal of Hypertension, 2012, 30, 34-37.	0.5	2
136	PÃ©ptido similar al glucagÃ³n tipo 1 y supervivencia de la cÃ©lula cardiaca. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2012, 59, 561-569.	0.8	8
137	Prevalence of left ventricular diastolic dysfunction in European populations based on cross-validated diagnostic thresholds. Cardiovascular Ultrasound, 2012, 10, 10.	1.6	68
138	Blockade of TGF-<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi mathvariant="bold-italic">Î²</mml:mi></mml:math>1 Signalling Inhibits Cardiac NADPH Oxidase Overactivity in Hypertensive Rats. Oxidative Medicine and Cellular Longevity, 2012, 2012, 1-8.	4.0	14
139	GLP-1 and cardioprotection: from bench to bedside. Cardiovascular Research, 2012, 94, 316-323.	3.8	93
140	The influence of obesity on the assessment of carotid intimaâ€•media thickness. Journal of Clinical Ultrasound, 2012, 40, 479-485.	0.8	7
141	Cardiotrophin-1 in hypertensive heart disease. Endocrine, 2012, 42, 9-17.	2.3	22
142	New Targets to Treat the Structural Remodeling of the Myocardium. Journal of the American College of Cardiology, 2011, 58, 1833-1843.	2.8	147
143	Association of the peroxisome proliferator-activated receptor Î± gene L162V polymorphism with stage C heart failure. Journal of Hypertension, 2011, 29, 876-883.	0.5	8
144	Hypertensive left ventricular hypertrophy risk: beyond adaptive cardiomyocytic hypertrophy. Journal of Hypertension, 2011, 29, 17-26.	0.5	64

#	Article	IF	Citations
145	Towards the molecular diagnosis of hypertensive heart disease?. Journal of Hypertension, 2011, 29, 660-662.	0.5	1
146	Altered regulation of the epithelial sodium channel in hypertension. From genes to therapeutics. Journal of Hypertension, 2011, 29, 204-206.	0.5	0
147	Aspectos emergentes del sistema renina-angiotensina en la diabetes: Â¿cÃ³mo abordar su traslaciÃ³n a la clÃnica?. Revista Espanola De Cardiologia Suplementos, 2011, 11, 37-41.	0.2	0
148	Urinary proteomics in cardiovascular disease: Achievements, limits and hopes. Proteomics - Clinical Applications, 2011, 5, 222-232.	1.6	11
149	Angiotensin II and Myocardial Remodeling: Do Macrophages Hold the Key?. American Journal of Hypertension, 2011, 24, 626-627.	2.0	0
150	HIF-1-mediated up-regulation of cardiotrophin-1 is involved in the survival response of cardiomyocytes to hypoxia. Cardiovascular Research, 2011, 92, 247-255.	3.8	42
151	Cardiotrophin-1 plasma levels are associated with the severity of hypertrophy in hypertrophic cardiomyopathy. European Heart Journal, 2011, 32, 177-183.	2.2	26
152	Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 300, H1361-H1372.	3.2	70
153	A role for cardiotrophin-1 in myocardial remodeling induced by aldosterone. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 301, H2372-H2382.	3.2	56
154	The A640G CYBA polymorphism associates with subclinical atherosclerosis in diabetes. Frontiers in Bioscience - Elite, 2011, E3, 1467-1474.	1.8	5
155	Protective effect of the 1742(C/G) polymorphism of human cardiotrophin-1 against left ventricular hypertrophy in essential hypertension. Journal of Hypertension, 2010, 28, 2219-2226.	0.5	6
156	Is leptin involved in phagocytic NADPH oxidase overactivity in obesity? Potential clinical implications. Journal of Hypertension, 2010, 28, 1944-1950.	0.5	44
157	Myocardial remodeling after infarction: the role of myofibroblasts. Nature Reviews Cardiology, 2010, 7, 30-37.	13.7	612
158	Corrigendum to â€œPreliminary characterisation of the promoter of the human p22phoxgene: Identification of a new polymorphism associated with hypertensionâ€•[FEBS Lett. 542 (2003) 27-31]. FEBS Letters, 2010, 584, 4709-4709.	2.8	0
159	Is the Deficiency of the Long Isoform of Cellular FLICE-Inhibitory Protein Involved in Myocardial Remodeling?. Hypertension, 2010, 56, 1045-1046.	2.7	1
160	Role of lysyl oxidase in myocardial fibrosis: from basic science to clinical aspects. American Journal of Physiology - Heart and Circulatory Physiology, 2010, 299, H1-H9.	3.2	209
161	Filling Pressures and Collagen Metabolism in Hypertensive Patients With Heart Failure and Normal Ejection Fraction. Hypertension, 2010, 55, 1418-1424.	2.7	100
162	A Translational Approach to Hypertensive Heart Disease. Hypertension, 2010, 55, 1-8.	2.7	98

#	Article	IF	Citations
163	Association Between Left Ventricular Mass and Telomere Length in a Population Study. American Journal of Epidemiology, 2010, 172, 440-450.	3.4	53
164	G Proteinâ€“Coupled Receptor Kinase 2 Plays a Relevant Role in Insulin Resistance and Obesity. Diabetes, 2010, 59, 2407-2417.	0.6	99
165	Altered degradation of extracellular matrix in myocardial remodelling: the growing role of cathepsins and cystatins. Cardiovascular Research, 2010, 87, 591-592.	3.8	20
166	Cardiac resynchronization therapy-induced left ventricular reverse remodelling is associated with reduced plasma annexin A5. Cardiovascular Research, 2010, 88, 304-313.	3.8	25
167	Circulating Biomarkers of Collagen Metabolism in Cardiac Diseases. Circulation, 2010, 121, 1645-1654.	1.6	195
168	Myocardial Fibrosis as an Early Manifestation of Hypertrophic Cardiomyopathy. New England Journal of Medicine, 2010, 363, 552-563.	27.0	566
169	Serum levels of matrix metalloproteinase-10 are associated with the severity of atherosclerosis in patients with chronic kidney disease. Kidney International, 2010, 78, 1275-1280.	5.2	37
170	Vascular effects of cardiotrophin-1: a role in hypertension?. Journal of Hypertension, 2010, 28, 1261-1272.	0.5	28
171	Do microRNAs regulate myocardial fibrosis?. Nature Clinical Practice Cardiovascular Medicine, 2009, 6, 88-89.	3.3	10
172	Losartan Metabolite EXP3179 Blocks NADPH Oxidase-Mediated Superoxide Production by Inhibiting Protein Kinase C. Hypertension, 2009, 54, 744-750.	2.7	62
173	Increased CD74 expression in human atherosclerotic plaques: contribution to inflammatory responses in vascular cells. Cardiovascular Research, 2009, 83, 586-594.	3.8	55
174	Prevalence of Left Ventricular Diastolic Dysfunction in a General Population. Circulation: Heart Failure, 2009, 2, 105-112.	3.9	291
175	Impact of Treatment on Myocardial Lysyl Oxidase Expression and Collagen Cross-Linking in Patients With Heart Failure. Hypertension, 2009, 53, 236-242.	2.7	144
176	Insulin-induced NADPH oxidase activation promotes proliferation and matrix metalloproteinase activation in monocytes/macrophages. Free Radical Biology and Medicine, 2009, 46, 1058-1067.	2.9	40
177	TORAFIC study protocol: torasemide prolonged release versus furosemide in patients with chronic heart failure. Expert Review of Cardiovascular Therapy, 2009, 7, 897-904.	1.5	15
178	Towards a New Paradigm About Hypertensive Heart Disease. Medical Clinics of North America, 2009, 93, 637-645.	2.5	36
179	Genomics and Proteomics in Heart Failure Research. Revista Espanola De Cardiologia (English Ed), 2009, 62, 305-313.	0.6	4
180	Insulin resistance determines phagocytic nicotinamide adenine dinucleotide phosphate oxidase overactivation in metabolic syndrome patients. Journal of Hypertension, 2009, 27, 1420-1430.	0.5	13

#	Article	IF	Citations
181	Obesity-related cardiac and vascular structural alterations: beyond blood pressure overload. Journal of Hypertension, 2009, 27, 1750-1752.	0.5	12
182	The angiotensin-converting enzyme insertion/deletion polymorphism is associated with phagocytic NADPH oxidase-dependent superoxide generation: potential implication in hypertension. Clinical Science, 2009, 116, 233-240.	4.3	8
183	Association of plasma cardiotrophin-1 with stage C heart failure in hypertensive patients: Potential diagnostic implications. Journal of Hypertension, 2009, 27, 418-424.	0.5	45
184	Reninâ€“Angiotensinâ€“Aldosterone System and Cardiomyocyte Apoptosis in Hypertensive Heart Disease. , 2009, , 143-150.		1
185	Left Ventricular Hypertrophy and Treatment with Renin Angiotensin System Inhibition. , 2009, , 103-119.		3
186	Cooperative Cardiovascular Disease Research Network (RECAVA). Revista Espanola De Cardiologia (English Ed), 2008, 61, 58-65.	0.6	8
187	Efecto vasodilatador de la ghrelina en la aorta de rata. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2008, 55, 448-453.	0.8	5
188	Serum Soluble ST2 as a Biochemical Marker of Acute Heart Failure. Journal of the American College of Cardiology, 2008, 52, 1466-1467.	2.8	22
189	Fibrosis. Journal of the American College of Cardiology, 2008, 52, 2029-2031.	2.8	41
190	Overexpression of human truncated peroxisome proliferator-activated receptor Â induces apoptosis in HL-1 cardiomyocytes. Cardiovascular Research, 2008, 79, 458-463.	3.8	11
191	Molecular Mechanisms of Atherosclerosis in Metabolic Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 2187-2194.	2.4	51
192	A translational approach to myocardial remodelling. Cardiovascular Research, 2008, 81, 409-411.	3.8	8
193	Impact of collagen type I turnover on the long-term response to cardiac resynchronization therapy. European Heart Journal, 2008, 29, 898-906.	2.2	27
194	Cardiotrophin-1 is expressed in adipose tissue and upregulated in the metabolic syndrome. American Journal of Physiology - Endocrinology and Metabolism, 2008, 294, E52-E60.	3.5	64
195	AT₁receptor antagonism attenuates target organ effects of salt excess in SHRs without affecting pressure. American Journal of Physiology - Heart and Circulatory Physiology, 2008, 294, H853-H858.	3.2	82
196	Effects of Aldosterone on the Heart. Hypertension, 2008, 52, 462-464.	2.7	17
197	A synthetic peptide from transforming growth factor-Â1 type III receptor prevents myocardial fibrosis in spontaneously hypertensive rats. Cardiovascular Research, 2008, 81, 601-609.	3.8	89
198	Myocardial fibrosis in chronic kidney disease: potential benefits of torasemide. Kidney International, 2008, 74, S19-S23.	5.2	54

#	Article	IF	Citations
199	Biochemical markers of myocardial remodelling in hypertensive heart disease. Cardiovascular Research, 2008, 81, 509-518.	3.8	73
200	Aldosterone Induces Cardiotrophin-1 Expression in HL-1 Adult Cardiomyocytes. Endocrinology, 2008, 149, 4970-4978.	2.8	39
201	The Proinflammatory Mediator CD40 Ligand Is Increased in the Metabolic Syndrome and Modulated by Adiponectin. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2319-2327.	3.6	33
202	Mechanical dyssynchrony: another mechanism of left ventricular dysfunction in hypertension?. Journal of Hypertension, 2008, 26, 399-402.	0.5	0
203	Diagnosis and Treatment of Myocardial Fibrosis in Hypertensive Heart Disease. Circulation Journal, 2008, 72, A8-A12.	1.6	20
204	NADPH oxidase CYBA polymorphisms, oxidative stress and cardiovascular diseases. Clinical Science, 2008, 114, 173-182.	4.3	90
205	Loss of myocardial LIF receptor in experimental heart failure reduces cardiotrophin-1 cytoprotection. A role for neurohumoral agonists?. Cardiovascular Research, 2007, 75, 536-545.	3.8	36
206	Upregulation of myocardial Annexin A5 in hypertensive heart disease: association with systolic dysfunction. European Heart Journal, 2007, 28, 2785-2791.	2.2	37
207	Association of Increased Plasma Cardiotrophin-1 With Inappropriate Left Ventricular Mass in Essential Hypertension. Hypertension, 2007, 50, 977-983.	2.7	44
208	Phagocytic NADPH Oxidase-Dependent Superoxide Production Stimulates Matrix Metalloproteinase-9. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 587-593.	2.4	82
209	The Role of Myocardial Collagen Network in Hypertensive Heart Disease. Current Hypertension Reviews, 2007, 3, 1-7.	0.9	5
210	Telomere dysfunction in hypertension. Journal of Hypertension, 2007, 25, 2185-2192.	0.5	49
211	A novel CYBA variant, the â€“675A/T polymorphism, is associated with essential hypertension. Journal of Hypertension, 2007, 25, 1620-1626.	0.5	34
212	Association of depressed cardiac gp130-mediated antiapoptotic pathways with stimulated cardiomyocyte apoptosis in hypertensive patients with heart failure. Journal of Hypertension, 2007, 25, 2148-2157.	0.5	44
213	Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). Journal of Hypertension, 2007, 25, 1958-1966.	0.5	95
214	Mechanisms of Cardiac Fibrosis in Hypertension. Journal of Clinical Hypertension, 2007, 9, 546-550.	2.0	183
215	The Inhibitory Effect of Leptin on Angiotensin II-Induced Vasoconstriction in Vascular Smooth Muscle Cells Is Mediated via a Nitric Oxide-Dependent Mechanism. Endocrinology, 2007, 148, 324-331.	2.8	110
216	Identification of a Potential Cardiac Antifibrotic Mechanism of Torasemide in Patients With Chronic Heart Failure. Journal of the American College of Cardiology, 2007, 50, 859-867.	2.8	118

#	Article	IF	Citations
217	Oxidative Stress, Endothelial Dysfunction and Cerebrovascular Disease. Cerebrovascular Diseases, 2007, 24, 24-29.	1.7	65
218	Hypertensive Heart Disease. , 2007, , 621-631.		2
219	Avances en cardiopatÃa hipertensiva. Mecanismos de remodelado implicados en la transiciÃ³n de la hipertrofia a la insuficiencia cardiaca. Revista Espanola De Cardiologia Suplementos, 2007, 7, 14F-21F.	0.2	0
220	Highlights from International Congress. High Blood Pressure and Cardiovascular Prevention, 2006, 13, 61-72.	2.2	0
221	C-Reactive Protein Induces Matrix Metalloproteinase-1 and -10 in Human Endothelial Cells. Journal of the American College of Cardiology, 2006, 47, 1369-1378.	2.8	168
222	Alterations in the Pattern of Collagen Deposition May Contribute to the Deterioration of Systolic Function in Hypertensive Patients With Heart Failure. Journal of the American College of Cardiology, 2006, 48, 89-96.	2.8	214
223	A Biomarker of Myocardial Fibrosis Predicts Long-Term Response to Cardiac Resynchronization Therapy. Journal of the American College of Cardiology, 2006, 47, 2335-2337.	2.8	18
224	Review of the molecular pharmacology of Losartan and its possible relevance to stroke prevention in patients with hypertension. Clinical Therapeutics, 2006, 28, 832-848.	2.5	29
225	Differential hypertrophic effects of cardiotrophin-1 on adult cardiomyocytes from normotensive and spontaneously hypertensive rats. Journal of Molecular and Cellular Cardiology, 2006, 41, 902-913.	1.9	43
226	Angiotensin II and Myocardial Fibrosis, Clinical Implications. , 2006, , 193-213.		0
227	Blood pressure control in patients with chronic renal insufficiency in Spain: a cross-sectional study. Journal of Hypertension, 2006, 24, 395-402.	0.5	33
228	The inhibitory effect of leptin on angiotensin II-induced vasoconstriction is blunted in spontaneously hypertensive rats. Journal of Hypertension, 2006, 24, 1589-1597.	0.5	37
229	Apoptosis in hypertensive heart disease: a clinical approach. Current Opinion in Cardiology, 2006, 21, 288-294.	1.8	23
230	The C242T CYBA polymorphism of NADPH oxidase is associated with essential hypertension. Journal of Hypertension, 2006, 24, 1299-1306.	0.5	83
231	Arterial Stiffness and Extracellular Matrix. , 2006, 44, 76-95.		71
232	Oxidative stress and atherosclerosis in early chronic kidney disease. Nephrology Dialysis Transplantation, 2006, 21, 2686-2690.	0.7	68
233	Altered cardiac expression of peroxisome proliferator-activated receptor-isoforms in patients with hypertensive heart disease. Cardiovascular Research, 2006, 69, 899-907.	3.8	46
234	Myocardial fibrosis, impaired coronary hemodynamics, and biventricular dysfunction in salt-loaded SHR. American Journal of Physiology - Heart and Circulatory Physiology, 2006, 290, H1503-H1509.	3.2	70

#	Article	IF	Citations
235	Phagocytic NADPH Oxidase Overactivity Underlies Oxidative Stress in Metabolic Syndrome. Diabetes, 2006, 55, 209-215.	0.6	121
236	Remodeling in Hypertensive Heart Disease: Role of the Renin-Angiotensin-Aldosterone System. , 2006, , 177-189.		0
237	The use of collagen-derived serum peptides for the clinical assessment of hypertensive heart disease. Journal of Hypertension, 2005, 23, 1445-1451.	0.5	65
238	Is plasma cardiotrophin-1 a marker of hypertensive heart disease?. Journal of Hypertension, 2005, 23, 625-632.	0.5	72
239	New directions in the assessment and treatment of hypertensive heart disease. Current Opinion in Nephrology and Hypertension, 2005, 14, 428-434.	2.0	13
240	Usefulness of plasma cardiotrophin-1 in assessment of left ventricular hypertrophy regression in hypertensive patients. Journal of Hypertension, 2005, 23, 2297-2304.	0.5	42
241	Increased phagocytic nicotinamide adenine dinucleotide phosphate oxidaseâ€“dependent superoxide production in patients with early chronic kidney disease. Kidney International, 2005, 68, S71-S75.	5.2	45
242	Oxidative stress and vascular remodelling. Experimental Physiology, 2005, 90, 457-462.	2.0	129
243	NADPH Oxidaseâ€“Dependent Superoxide Production Is Associated With Carotid Intima-Media Thickness in Subjects Free of Clinical Atherosclerotic Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1452-1457.	2.4	62
244	Monocyte cyclooxygenase-2 overactivity: a new marker of subclinical atherosclerosis in asymptomatic subjects with cardiovascular risk factors?. European Heart Journal, 2005, 26, 153-158.	2.2	42
245	NADPH Oxidase-Mediated Oxidative Stress: Genetic Studies of thep22^{phox}Gene in Hypertension. Antioxidants and Redox Signaling, 2005, 7, 1327-1336.	5.4	86
246	Characterization of the protective effects of cardiotrophin-1 against non-ischemic death stimuli in adult cardiomyocytes. Cytokine, 2005, 30, 282-292.	3.2	45
247	Serum Markers of Fibrillar Collagen Metabolism in Cardiac Diseases. , 2005, , 101-113.		0
248	Mechanisms of Disease: pathologic structural remodeling is more than adaptive hypertrophy in hypertensive heart disease. Nature Clinical Practice Cardiovascular Medicine, 2005, 2, 209-216.	3.3	143
249	Profibrotic Effects of Angiotensin II in the Heart. Hypertension, 2004, 43, 1164-1165.	2.7	21
250	Generation of eight adjacent mutations in a single step using a site-directed mutagenesis kit. Clinical Chemistry and Laboratory Medicine, 2004, 42, 384-6.	2.3	6
251	Surrogate Markers for Cardiovascular Disease: Structural Markers. Circulation, 2004, 109, IV-22-IV-30.	1.6	175
252	Different Effects of Antihypertensive Therapies Based on Losartan or Atenolol on Ultrasound and Biochemical Markers of Myocardial Fibrosis. Circulation, 2004, 110, 552-557.	1.6	157

#	Article	IF	Citations
253	Functional Effect of the p22 phox â˜930 A/G Polymorphism on p22 phox Expression and NADPH Oxidase Activity in Hypertension. Hypertension, 2004, 44, 163-169.	2.7	89
254	Increased Collagen Type I Synthesis in Patients With Heart Failure of Hypertensive Origin. Circulation, 2004, 110, 1263-1268.	1.6	392
255	Fibrosis in hypertensive heart disease: role of the renin-angiotensin-aldosterone system. Medical Clinics of North America, 2004, 88, 83-97.	2.5	83
256	Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. Journal of the American College of Cardiology, 2004, 43, 2028-2035.	2.8	248
257	Peroxisome Proliferator-Activated Receptor ?? and Hypertensive Heart Disease. Drugs, 2004, 64, 9-18.	10.9	19
258	Angiotensin II and the hypertensive heart. Journal of Hypertension, 2004, 22, 879-882.	0.5	5
259	Role of matrix metalloproteinases in hypertension-associated cardiac fibrosis. Current Opinion in Nephrology and Hypertension, 2004, 13, 197-204.	2.0	40
260	Association of increased phagocytic NADPH oxidase-dependent superoxide production with diminished nitric oxide generation in essential hypertension. Journal of Hypertension, 2004, 22, 2169-2175.	0.5	92
261	Preliminary characterisation of the promoter of the human p22^{phox} gene: identification of a new polymorphism associated with hypertension. FEBS Letters, 2003, 542, 27-31.	2.8	86
262	Independent Association of Fibrinogen with Carotid Intima-Media Thickness in Asymptomatic Subjects. Cerebrovascular Diseases, 2003, 16, 356-362.	1.7	28
263	Cardiomyocyte apoptosis in hypertensive cardiomyopathy. Cardiovascular Research, 2003, 59, 549-562.	3.8	110
264	Involvement of cardiomyocyte survivalâ€“apoptosis balance in hypertensive cardiac remodeling. Expert Review of Cardiovascular Therapy, 2003, 1, 293-307.	1.5	9
265	Clinical implications of apoptosis in hypertensive heart disease. American Journal of Physiology - Heart and Circulatory Physiology, 2003, 284, H1495-H1506.	3.2	45
266	The A1166C polymorphism of the AT1 receptor gene is associated with collagen type I synthesis and myocardial stiffness in hypertensives. Journal of Hypertension, 2003, 21, 2085-92.	0.5	21
267	Ultrasonic Backscatter and Serum Marker of Cardiac Fibrosis in Hypertensives. Hypertension, 2002, 39, 923-928.	2.7	68
268	Leptin Inhibits Angiotensin II-Induced Intracellular Calcium Increase and Vasoconstriction in the Rat Aorta. Endocrinology, 2002, 143, 3555-3560.	2.8	97
269	Losartan-Dependent Regression of Myocardial Fibrosis Is Associated With Reduction of Left Ventricular Chamber Stiffness in Hypertensive Patients. Circulation, 2002, 105, 2512-2517.	1.6	572
270	Stimulation of Cardiac Apoptosis in Essential Hypertension. Hypertension, 2002, 39, 75-80.	2.7	102

#	Article	IF	Citations
271	Ultrasonic Backscatter and Diastolic Function in Hypertensive Patients. Hypertension, 2002, 40, 239-243.	2.7	28
272	Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. Journal of Hypertension, 2002, 20, 1855-1864.	0.5	107
273	Torasemide in chronic heart failure: results of the TORIC study. European Journal of Heart Failure, 2002, 4, 507-513.	7.1	215
274	Regulation of Myocardial Fibrillar Collagen by Angiotensin II. A Role in Hypertensive Heart Disease?. Journal of Molecular and Cellular Cardiology, 2002, 34, 1585-1593.	1.9	106
275	Corrigendum to â€˜Torasemide in chronic heart failure: results of the TORIC studyâ€™ [Eur. J. Heart Fail. 4 (2002) 507-513]. European Journal of Heart Failure, 2002, 4, 667-667.	7.1	3
276	Emerging role of matrix metalloproteinases in the pathophysiology of cardiac diseases. European Journal of Clinical Investigation, 2002, 32, 291-294.	3.4	13
277	Pathophysiologic and therapeutic importance of tissue ACE: a consensus report. Cardiovascular Drugs and Therapy, 2002, 16, 149-160.	2.6	118
278	Effects of Antihypertensive Agents on the Left Ventricle. American Journal of Cardiovascular Drugs, 2001, 1, 263-279.	2.2	20
279	A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease. Journal of Hypertension, 2001, 19, 1871-1876.	0.5	76
280	Clinical aspects of hypertensive myocardial fibrosis. Current Opinion in Cardiology, 2001, 16, 328-335.	1.8	116
281	The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. American Journal of Cardiology, 2001, 88, 1-20.	1.6	202
282	Is the balance between nitric oxide and superoxide altered in spontaneously hypertensive rats with endothelial dysfunction?. Nephrology Dialysis Transplantation, 2001, 16, 2-5.	0.7	46
283	The loop diuretic torasemide interferes with endothelinâ€1 actions in the aorta of hypertensive rats. Nephrology Dialysis Transplantation, 2001, 16, 18-21.	0.7	47
284	Usefulness of Serum Carboxy-Terminal Propeptide of Procollagen Type I in Assessment of the Cardioreparative Ability of Antihypertensive Treatment in Hypertensive Patients. Circulation, 2001, 104, 286-291.	1.6	244
285	Effects of loop diuretics on angiotensin Iiâ€stimulated vascular smooth muscle cell growth. Nephrology Dialysis Transplantation, 2001, 16, 14-17.	0.7	118
286	Biochemical Assessment of Myocardial Fibrosis in Hypertensive Heart Disease. Hypertension, 2001, 38, 1222-1226.	2.7	157
287	Vascular oxidant stress: Molecular mechanisms and pathophysiological implications. Journal of Physiology and Biochemistry, 2000, 56, 57-64.	3.0	101
288	Mechanisms of Increased Susceptibility to Angiotensin Iiâ€“Induced Apoptosis in Ventricular Cardiomyocytes of Spontaneously Hypertensive Rats. Hypertension, 2000, 36, 1065-1071.	2.7	59

#	Article	IF	Citations
289	Insulin-like growth factor I in essential hypertension. Kidney International, 1999, 55, 744-759.	5.2	28
290	Losartan inhibits the post-transcriptional synthesis of collagen type I and reverses left ventricular fibrosis in spontaneously hypertensive rats. Journal of Hypertension, 1999, 17, 107-114.	0.5	111
291	Decreased excretion of nitrate and nitrite in essential hypertensives with renal vasoconstriction. Kidney International, 1998, 54, S10-S13.	5.2	5
292	Apoptosis in hypertensive heart disease. Current Opinion in Cardiology, 1998, 13, 317-326.	1.8	64
293	Tissue availability of insulin-like growth factor I is inversely related to insulin resistance in essential hypertension. Journal of Hypertension, 1998, 16, 863-870.	0.5	13
294	Is the tissue availability of circulating insulin-like growth factor I involved in organ damage and glucose regulation in hypertension?. Journal of Hypertension, 1997, 15, 1159-1165.	0.5	12
295	Angiotensin Converting Enzyme Inhibition Corrects Na+/H+ Exchanger Overactivity in Essential Hypertension. American Journal of Hypertension, 1997, 10, 84-93.	2.0	24
296	Quinapril Inhibits c-Myc Expression and Normalizes Smooth Muscle Cell Proliferation in Spontaneously Hypertensive Rats. American Journal of Hypertension, 1997, 10, 1147-1152.	2.0	14
297	Toward the biochemical assessment of myocardial fibrosis in hypertensive patients. American Journal of Cardiology, 1995, 76, 14D-17D.	1.6	15
298	Quinapril decreases myocardial accumulation of extracellular matrix components in spontaneously hypertensive rats. American Journal of Hypertension, 1995, 8, 815-822.	2.0	44
299	Enhanced Na ⁺ -H ⁺ Exchanger Activity and NHE-1 mRNA Expression in Lymphocytes From Patients With Essential Hypertension. Hypertension, 1995, 25, 356-364.	2.7	21
300	Treatment With Lisinopril Normalizes Serum Concentrations of Procollagen Type III Amino-Terminal Peptide in Patients With Essential Hypertension. American Journal of Hypertension, 1994, 7, 52-58.	2.0	39
301	Immunohistochemical detection of chloride/bicarbonate anion exchangers in human liver. Hepatology, 1994, 19, 1400-1406.	7.3	159
302	Current work in the cell biology of left ventricular hypertrophy. Current Opinion in Cardiology, 1994, 9, 512-519.	1.8	7
303	Abnormal expression of anion exchanger genes in primary biliary cirrhosis. Gastroenterology, 1993, 105, 572-578.	1.3	132
304	Elevated Levels of Parathyroid Hormone in Essential Hypertensive Patients With Increased Erythrocyte Potassium Efflux. American Journal of Hypertension, 1991, 4, 714-718.	2.0	2
305	Abnormal sympathetic and renal response to sodium restriction in compensated cirrhosis. Gastroenterology, 1991, 101, 1354-1360.	1.3	14
306	Uremia and Red Blood Cell Sodium Transport. Nephron, 1986, 43, 155-157.	1.8	9

#	Article	IF	Citations
307	Intracerebroventricular Infusion of Sodium Chloride-Rich Artificial Cerebrospinal Fluid in Rats Induces Natriuresis and Releases An Inhibitor of Prostaglandin Synthesis. Clinical Science, 1984, 66, 621-624.	4.3	9
308	From cardiorenal syndromes to cardionephrology: a reflection of nephrologists on renocardiac syndromes. CKJ: Clinical Kidney Journal, 0, , .	2.9	3